Table 1.
Summary of Sexual Relationships scores for scleroderma and comparison samples
| Mean age, | PAIS-SR sexual | dcSSc |
lcSSc |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Study | Sample characteristics | n | years | relations | P-value | Hedges's g | P-value | Hedges's g | |
| Present study | dcSSc, mean illness duration: 7.1 years | 39 | 51 | 6.1 ± 4.2 | – | – | 0.034 | 0.40 | |
| lcSSc, mean illness duration: 9.6 years | 99 | 53 | 4.4 ± 4.2 | – | – | ||||
| Breast cancer | |||||||||
| Arena et al. [17] | 9% Stage 0, 59% Stage I, 32% Stage II breast cancera | 56 | 49a | 1.8 ± 0.1 | <0.001 | 1.57 | <0.001 | 0.74 | |
| 55% mastectomy, 33% lumpectomy, 24% reconstructive surgerya | |||||||||
| 46% radiotherapy, 44% chemotherapya | |||||||||
| Kreitler et al. [21] | 59% Stage I, 41% Stage II breast cancer | 96 | 53 | 3.4 ± 3.9 | <0.001 | 0.68 | 0.088 | 0.24 | |
| 31% surgery, 54% surgery + radiation or chemotherapy, 15% surgery + radiation + chemotherapy | |||||||||
| Petronis et al. [19] | 5% Stage 0, 57% Stage I, 38% Stage II breast cancerb | 142 | 54b | 1.6 ± 0.6 | <0.001 | 2.24 | <0.001 | 1.01 | |
| 41% mastectomy, 58% lumpectomy, 22% reconstructive surgery | |||||||||
| 60% radiotherapy (19% recent), 38% chemotherapy (13% recent) | |||||||||
| HIV positive | |||||||||
| Karus et al. [18] | 41% asymptomatic, 41% symptomatic, 19% AIDSc | 139 | 35c | 4.4 ± 3.8 | 0.019 | 0.43 | 0.924 | −0.01 | |
| Siegel et al. [20] | 10% asymptomatic, 43% symptomatic, 47% AIDS | 73 | 36 | 4.5 ± 3.9 | 0.043 | 0.40 | 0.887 | −0.02 | |
| 1994–96 | Mean 11.3 illness-related symptoms | ||||||||
| 2000–02 | 10% asymptomatic, 43% symptomatic, 47% AIDS | 73 | 37 | 5.8 ± 4.1 | 0.751 | 0.06 | 0.026 | −0.35 | |
| Mean 11.4 illness-related symptoms | |||||||||
| Gynaecological cancer | |||||||||
| Molassiotis | 57% ovarian, 32% cervical, 11% endometriald | 40 | 51d | 7.3 ± 4.3 | 0.200 | −0.29 | <0.001 | −0.69 | |
| et al. [22] | Mean illness duration 4.4 yearsd | ||||||||
aSample characteristics and mean age based on 78 patients, only 56 of whom were administered the PAIS-SR.bSample characteristics and mean age based on 237 patients, only 142 of whom were administered the PAIS-SR.cSample characteristics and mean age based on 146 patients, only 139 of whom were administered the PAIS-SR.dSample characteristics and mean age based on 62 patients, only 40 of whom were administered the PAIS-SR.